)
)
Kyverna Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Kyverna Therapeutics Inc
Access all reports
Kyverna Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for autoimmune diseases. The company focuses on chimeric antigen receptor (CAR) T-cell therapies, which are designed to reset the immune system and potentially offer sustained treatment-free remission for patients. Kyverna’s main product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy currently in clinical trials for various autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Additionally, Kyverna is developing KYV-201, an allogeneic CAR T-cell therapy, and exploring treatments for other autoimmune diseases including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.
Latest articles
)
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
)
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
)
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
Ticker symbol
KYTX
Country
🇺🇸 United States